Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that its
branded marketing subsidiary, ECR Pharmaceuticals will promote Urocit®-K
15mEq, potassium citrate extended release tablets to primary care
physicians beginning in April, 2010. Hi-Tech has a license agreement
with Mission Pharmacal Company, which will promote the product to
Urologists. Indicated for the treatment of kidney stones, UroCit®-K
15mEq is the maximum strength potassium citrate product available, and
provides convenient twice-a-day dosing Urocit-K 15 mEq offers kidney
stone sufferers the only twice-daily treatment at this dosage strength.
The new formulation provides patients with 50 percent more of the active
ingredient, potassium citrate, than Urocit-K 10 mEq. ECR Pharmaceuticals
will receive a percentage of gross profit based on prescriptions
generated by primary care physicians.
“UroCit®-K 15mEq is a highly
effective product, available in a convenient dosing regimen which will
increase patient compliance.”
"We are pleased to introduce another unique prescription branded product
to the primary care market," said David Seltzer, President and CEO of
Hi-Tech Pharmacal. "UroCit®-K 15mEq is a highly
effective product, available in a convenient dosing regimen which will
increase patient compliance."
Terry Herring, president of Mission Pharmacal’s Pharmaceutical Division
stated that, “We are pleased with our new arrangement with ECR. At
Mission, our goal is to bring innovative products to Physicians and
their patients. This partnership demonstrates our commitment to
delivering on that goal. Through this effort more patients will receive
better care. Mission Pharmacal continues to invest in research and
development to improve treatment outcomes of nephrolithiasis (kidney
stones) for physicians and patients.”
NYU Langone sets the standard for organ transplant care